BRIEF published on 08/12/2025 at 15:58, 10 months 13 days ago Franchissement de Seuil par Soleus Capital dans NICOX Droits De Vote Franchissement De Seuil Actions Nicox Soleus Capital
BRIEF published on 08/12/2025 at 15:58, 10 months 13 days ago Soleus Capital Crosses Threshold in NICOX Voting Rights Actions Threshold Crossing Nicox Soleus Capital
PRESS RELEASE published on 08/12/2025 at 15:53, 10 months 13 days ago Franchissement de seuils Déclaration de franchissement de seuils par Soleus Capital Management LP concernant NICOX SA, avec 4,63% des droits de vote suite à une cession d'actions Droits De Vote Franchissement De Seuils Cession D'actions Nicox SA Soleus Capital Management LP
BRIEF published on 08/08/2025 at 07:35, 10 months 18 days ago Nicox Expands Equity Financing with Vester Finance Equity Financing Nicox Share Dilution Phase 3 Results Vester Finance
BRIEF published on 08/08/2025 at 07:35, 10 months 18 days ago Nicox étend son financement par actions avec Vester Finance Financement Par Actions Nicox Dilution Des Actions Résultats De La Phase 3 Vester Finance
PRESS RELEASE published on 08/08/2025 at 07:30, 10 months 18 days ago Nicox Extends Existing Flexible Equity Financing Nicox extends PACEO equity line with Vester Finance by adding 5 million shares. NCX 470 Denali Phase 3 results expected in mid-August to mid-September 2025 Equity Financing Nicox Phase 3 Results NCX 470 Denali Vester Finance
PRESS RELEASE published on 08/08/2025 at 07:30, 10 months 18 days ago Nicox étend sa ligne de financement flexible existante Nicox prolonge sa ligne de financement avec Vester Finance, ajoutant 5M d'actions. Résultats attendus de l'étude Denali sur NCX 470 en août-septembre 2025 Nicox NCX 470 Financement Flexible Vester Finance Étude Denali
BRIEF published on 06/30/2025 at 07:35, 11 months 26 days ago Nicox Achieves Milestone in NCX 470 Phase 3 Clinical Trial Glaucoma Ocular Hypertension Phase 3 Trial Nicox NCX 470
BRIEF published on 06/30/2025 at 07:35, 11 months 26 days ago Nicox franchit une étape importante dans l'essai clinique de phase 3 du NCX 470 Essai De Phase 3 Nicox Hypertension Oculaire NCX 470 Glaucome
PRESS RELEASE published on 06/30/2025 at 07:30, 11 months 26 days ago Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial Nicox announces completion of Denali Phase 3 trial for NCX 470 eye drop, expecting results mid-August to mid-September 2025. NDA submission in the U.S. targeted for H1 2026 Phase 3 Trial Ophthalmology Nicox NCX 470 NDA Submission
Published on 06/26/2026 at 01:40, 7 hours 41 minutes ago UraniumX Announces DTC Eligibility for U.S. Traded Shares
Published on 06/25/2026 at 23:30, 9 hours 51 minutes ago Zeus North America Mining Corp. Signs Option Agreement to Acquire Mining Claims in Idaho
Published on 06/25/2026 at 22:30, 10 hours 51 minutes ago Fountain Asset Corp. Provides Corporate Update
Published on 06/25/2026 at 21:32, 11 hours 49 minutes ago BlackBerry Announces Election Results for the Company's Board of Directors
Published on 06/25/2026 at 15:30, 17 hours 51 minutes ago Silver Spruce Resources, Inc. Adds Mining, Energy, and Finance Development Expertise to the Board and Announces Director Resignation
Published on 06/26/2026 at 09:05, 16 minutes ago Avinox Wins Eurobike 2026 Award with its Smart Heart Rate Control System
Published on 06/26/2026 at 09:02, 19 minutes ago Kirchhoff Consult and DSW publish 2026 forecast report study: Number of transparent forecast reports in the DAX 40 rises
Published on 06/26/2026 at 09:00, 21 minutes ago Original-Research: LION E-Mobility AG (von NuWays AG): BUY
Published on 06/26/2026 at 09:00, 21 minutes ago Partners Group launches B Residences strategy to build flagship Breitling-branded luxury condominium tower in Miami
Published on 06/26/2026 at 07:00, 2 hours 21 minutes ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 2 hours 21 minutes ago Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/25/2026 at 18:45, 14 hours 36 minutes ago Avis Financier Semestriel SFCMC au 30 avril 2026
Published on 06/25/2026 at 18:30, 14 hours 51 minutes ago Avis financier semestriel SIEHM au 30 avril 2026
Published on 06/25/2026 at 17:50, 15 hours 31 minutes ago DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
